Under the agreement, the Medical College of Wisconsin laboratory will become the first laboratory to offer Transgenomic’s NuclearMitome Test. The test employs sequencing technology to identify mutations in 448 genes that are considered important for mitochondrial function.
Transgenomic says it is the most comprehensive genetic test available for mitochondrial disorders. Mitochondrial disorders are often caused by inherited or acquired mutations in mitochondrial DNA and can result in symptoms affecting multiple organ systems, including the liver, the brain and nervous system, kidneys, and cardiovascular function.
“The NuclearMitome Test is designed to improve the speed and precision of diagnosis for a host of mitochondrial disorders, allowing clinicians to plan the most effective treatment strategy,” said Craig Tuttle, chief executive officer of Transgenomic. “The Medical College of Wisconsin is a world-renowned institution with a robust presence in genomics and genetic testing. This collaboration allows Transgenomic to rapidly expand the commercial use of our NuclearMitome Test in addition to building out our offerings in whole genome and exome testing. We look forward to working with the Medical College of Wisconsin, and to building rapid value through these products.”
“Diagnosing mitochondrial disorders can be quite challenging and, until now, has typically involved the use of wide-ranging genetic and non-genetic tests as well as consultation with various medical specialties,” said Howard Jacob, Ph.D., director of the Human and Molecular Genetics Center at the Medical College of Wisconsin. “The ability to evaluate 400-plus genes with one diagnostic tool should shorten patients’ diagnostic odysseys and provide faster answers. We look forward to a successful partnership.”